Interní Med. 2014; 16(2): 62-66

Efficiency and safety of linagliptin - relevance to clinical practice

doc.MUDr.Martin Prázný, CSc., Ph.D., MUDr.Jan ©oupal
3. interní klinika VFN a 1. LF UK v Praze

Treatment of type 2 diabetes is based on lifestyle adjustments in combination with pharmacotherapy. Metformin is the first line therapy

and after metformin there are several groups of drugs that can be chosen. Dipeptidyl peptidase 4 inhibitors (gliptins) are modern antidiabetic

drugs affecting incretin system. All gliptins are effective and relatively safe. For most gliptins it is necessary to continuously

monitor renal and hepatic function. Linagliptin has advantages in minimal hepatic metabolism and minimal renal excretion. In daily

practice, it is not necessary to monitor liver and renal function during the treatment with linagliptin and thanks to minimal hepatic

metabolism of linagliptin there is minimal potential for drug interactions. Case report presented in this article provides an example of

use of linagliptin in the treatment of patients with type 2 diabetes, including therapeutic consideration that led to adding of linagliptin

for treatment of this patient.

Keywords: type 2 diabetes mellitus, DPP-4 inhibitors, linagliptin, treatment of diabetes

Published: April 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prázný M, ©oupal J. Efficiency and safety of linagliptin - relevance to clinical practice. Interní Med. 2014;16(2):62-66.
Download citation




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.